

January 29, 2008

To: Those in Adalimumab, The Only Fully Human Monoclonal ~~on Anti-Body~~

Eisai Co., Ltd., (Headquarters in Tokyo, President: Haruo Naito), Abbott Japan Co., Ltd., (Pharmaceutical Products Group in Osaka, President: Glenn S. Warner), and Abbott Biotechnology Ltd., (Director and President: Thomas C. Freyman) concluded a co-development license agreement for the following additional indications for adalimumab: ankylosing spondylitis, juvenile rheumatoid arthritis, and ulcerative colitis. Abbott and Eisai will cooperate in the development of these three new indications, in addition to rheumatoid arthritis and psoriasis, where applications for approval have already been submitted to the Ministry of Health and Welfare, and Crohn's disease, which is under investigation in Phase II/III studies. re,5ei catiokn d7rs.

Reference

1. Glossaries

1) TNF

The tumor necrosis factors (TNF's) are a group of cytokines (i.e., substances mediating cell-cell interactions) that have been found to damage tumor cells. TNFs are produced by many types of cells such as macrophages, lymphocytes, and vascular endothelial cells, and are known to cause and enhance inflammatory responses and to activate inflammatory cells.

2) Monoclonal antibody

A monoclonal antibody is a protein produced from clones of a single antibody-producing cell (called monoclonal). Antibody molecules produced using this method share identical amino acid sequences and other characteristics.

3) Ankylosing spondylitis (AS)

Ankylosing spondylitis (AS) is a disease characterized by spinal stiffness. Although the causes of AS are still unclear, evidence suggests that AS is prevalent among individuals having particular types of genes. As one type of rheumatoid factor-negative spondylarthritis, AS causes inflammation of the spine, sacroiliac joints, and hip joints, as well as other sites where ligaments attach to bone, which eventually results in bony ankylosis of the spine and joints.

4) Juvenile rheumatoid arthritis (JRA)

2. Eisai's Commitment to Immunology

Eisai's strength has been in low-molecular-weight drugs but is currently addressing biologics aggressively. In April 2007 Eisai acquired Morphotek, Inc., a bio-venture specializing in research and development of antibody drugs in the United States, and is now involved in the creation of antibody drugs for the treatment of cancer, rheumatoid arthritis and infections using Morphotek's unique technologies, such as Human Morphodoma[®] and Libradoma[™]. In addition, Eisai is investigating immunotherapy for Alzheimer disease in cooperation with BioArctic Neuroscience Inc. in Sweden, and